Number of the records: 1  

A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)

  1. TitleA Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)
    article

    article

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.